Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: An exploratory study

Journal of Neuro-Oncology

Volumn 89, Issue 2, 2008, Pages 211-218

  Preusser, M ^a   Gelpi, E ^b   Rottenfusser, A ^a   Dieckmann, K ^a   Widhalm, G ^a   Dietrich, W ^a   Bertalanffy, A ^a   Prayer, D ^a   Hainfellner, J A ^b   Marosi, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; Epithelial Growth Factor Receptor; Malignant glioma; Prognosis; Tyrosine kinase inhibitor

Indexed keywords

BIOLOGICAL MARKER; DACARBAZINE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FOTEMUSTINE; GADOLINIUM; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACRANIAL HYPERTENSION; MALE; MONOTHERAPY; NAUSEA AND VOMITING; NEUROSURGERY; OLIGODENDROGLIOMA; PREDICTION; PROTEIN EXPRESSION; RASH; RECURRENT CANCER; TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE;

EID: 48749130017     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9608-3     Document Type: Article

References (29)

1. Stupp R, Hegi ME, van den Bent MJ et al (2006) Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180
2. Louis N, Ohgaki H, Wiestler OD, Cavanee WK (eds) (2007) World Health Organization classification of tumours of the central nervous system. IARC Press, Lyon
3. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453
4. Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700-707
5. Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962-6970
6. Learn CA, Hartzell TL, Wikstrand CJ et al (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10:3216-3224
7. Haas-Kogan DA, Prados MD, Tihan T et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887
8. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96
9. Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
10. Bareschino MA, Schettino C, Troiani T et al (2007) Erlotinib in cancer treatment. Ann Oncol 18(Suppl 6):vI35-41
11. Rocha-Lima CM, Soares HP, Raez LE et al (2007) EGFR targeting of solid tumors. Cancer Control 14:295-304
12. Prados MD, Lamborn KR, Chang S et al (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8:67-78
13. Franceschi E, Cavallo G, Lonardi S et al (2007) Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96:1047-1051
14. Halatsch ME, Schmidt U, Behnke-Mursch J et al (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74-89
15. Raizer JJ (2005) HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74:77-86
16. Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142
17. Lassman AB, Rossi MR, Raizer JJ et al (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11:7841-7850
18. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024
19. Friedman HS, Bigner DD (2005) Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 353:1997-1999
20. Macdonald DR, Cascino TL, Schold SC Jr. et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
21. Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746
22. Perren A, Weng LP, Boag AH et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260
23. Van Den Bent MJ, Brandes AA, Rampling R et al: Randomized phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme: EORTC 26034. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
24. Krishnan S, Brown PD, Ballman KV et al (2006) Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 65:1192-1199
25. Agero AL, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657-670
26. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921
27. Li B, Chang CM, Yuan M et al (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63:7443-7450
28. Marie Y, Carpentier AF, Omuro AM et al (2005) EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64:1444-1445
29. Cappuzzo F (2005) Erlotinib in gliomas: Should selection be based on EGFR and Akt analyses? J Natl Cancer Inst 97:868-869